A Humanized anti-c-erbB-2 monoclonal antibody for the treatment of breast cancer

Breast Cancer

Volumn 4, Issue 4, 1997, Pages 269-272

  Tokuda, Yutaka ^a   Okumura, Akira ^a   Ohta, Masatoshi ^a   Kubota, Mitsuhiro ^a   Ohnishi, Yasuyuki ^b   Shmamura, Kazuo ^a,c   Yoshimura, Masumi ^b   Ueyama, Yoshito ^a,b,c   Tamaoki, Norikazu ^a   Tajima, Tomoo ^a  

^a TOKAI UNIVERSITY   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Anti tumor effect; C erbB 2; Humanized monoclonal antibody; SCID mice

Indexed keywords

EID: 47349105910     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966520     Document Type: Conference Paper

References (15)

1. Yarden Y, Ullrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443-478, 1988.
2. Coussens L, Yang-Feng TL, Liao Y-C, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985. (Pubitemid 16169997)
3. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by human c-erbB-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986. (Pubitemid 16128786)
4. De Porter CR, Van Daele S, Van De Vijver M J, et al: The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 15:315-326, 1989.
5. Press MF, Cerdon-Cardo C, Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-962, 1990.
6. Schroff RW, Foon KA, Beatty SM, et al: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885, 1985. (Pubitemid 15161095)
7. Shawler DL, Bartholomew RM, Smith LM: Human immune response to multiple injection of murine monoclonal IgG. J Irnmunol 135:1530-1535, 1985. (Pubitemid 16237070)
8. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
9. Fendly BF, Winget M, Hudziak RM, et al: Characterization of monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/ neu gene product. Cancer Res 50:1550-1558, 1990. (Pubitemid 20090470)
10. Mosmann T: Rapid colorimetric assay for cellular growth and survival; Application to proliferation and cytotoxicity assays. J Imrnunol Methods 65:55-63, 1983. (Pubitemid 14203433)
11. Tokuda Y, Ebina N, Golub SH: The inhibitory effect of human a-interferon on the generation of lymphokine activated killer activity. Cancer Immunol ]mmunother 30:205-212, 1989. (Pubitemid 19282174)
12. Inaba M, Tashiro T, Kobayashi T, et al: Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Jpn J Cancer Res 79:517-522, 1988.
13. Ohnishi Y, Nakamura H, Yoshimura M, et al: Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody. Br J Cancer 71:969-973, 1995.
14. Tsai C-M, Yu D, Chang K-T, et al: Enhanced chemoresistance by elevation of p185 HER2 levels in HER2/ neu-transfected human lung cancer cells. J Natl Cancer Inst 87:682-684, 1995.
15. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonaI antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.